Returning 20 – 21st November 201
Boston

 Register Your Interest Now

POSTER SESSION

TEM1657 is a new small molecule for the topical and oral treatment of psoriasis

TEM1657 is a new small molecule for the topical and oral treatment of psoriasis

Temisis; Jean-François Ginglinger, CSO; Paul Hannewald, CEO

click here 

TEM1657 is a new small molecule for the topical and oral treatment of psoriasis (1)

FLX193:  A Potent, Selective CCR4 Antagonist for Allergic Disorders

Lisa Moore et al

click here 

TEM1657 is a new small molecule for the topical and oral treatment of psoriasis (2)

Neutralization of sFasL Directly Blocks Acantholysis without Immunosuppression: PC111, a monoclonal anti-Fas ligand (CD95L) antibody for pemphigus

 Roberta Lotti, Alessandra Marconi, Brydon Bennett, Carlo Pincelli

click here 

TEM1657 is a new small molecule for the topical and oral treatment of psoriasis (3)

A Phase 2, Randomized, Multicenter, Double-Blind, Active- and Vehicle- Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products TWIN High and TWIN Low for the Treatment of Acne Vulgaris for 12 Weeks

Ori Nov, Sol Gel Technologies

click here